Navigation Links
Selexis and NKT Therapeutics Enter Into Research Services Agreement
Date:9/1/2009

GENEVA, Sept. 1 /PRNewswire/ -- Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM). The Selexis INTEGRA-D2M(TM) platform enables the rapid isolation of production cell lines concomitant with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. Utilizing INTEGRA-D2M(TM), protein variant libraries of sizes larger than 10exp3 can be screened to identify lead compounds in less than 9 weeks. The selected CHO-based protein variant expressing clone can then be used directly for cGMP manufacturing.

"We are excited about the partnership with NKTT, who are recognized as leaders in the biology and therapeutic applications for modulating Natural Killer T cells," said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "Our novel and powerful INTEGRA-D2M(TM) platform, is able to support NKTT in rapidly making their final product decision while we also develop and deliver a high-performance production cell line ready for cGMP manufacturing."

"We greatly appreciate working with the team at Selexis and utilizing their powerful technology platform," adds Dr. Alem Truneh, Chief Scientific Officer and co-founder of NKT Therapeutics.

About Selexis INTEGRA-D2M(TM) Platform

Developed by Selexis over the last 2 years, the Selexis INTEGRA-D2M(TM) platform is a simple, non-robotic based approach enabling the screening of protein libraries in CHO cells. Such stable CHO-based libraries are developed in less than 9 weeks and enable the rapid selection of the best product candidates with respect to functionality (i.e. binding assay, neutralization assay) and titers (with reduced future COGS). The platform is also directly linked to the generation of high producing cell clones (for cGMP manufacturing) that are then generated in 12 weeks. The benefits of this approach are better preclinical decisions, dramatically shortened timelines and lower overall operational costs.

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

About NKT Therapeutics Inc.

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat asthma, cancer, autoimmune and infectious diseases. For more information on the company, please visithttp://www.nktrx.com/.


'/>"/>
SOURCE Selexis SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved ... join her with one on her shoulder and one on her arm. But she ... because of years of mitral valve prolapse. , The valves of the heart wouldn’t ...
(Date:5/3/2016)... ... May 03, 2016 , ... University of the People, ... launch of its Associates and Bachelor's degrees in Health Studies. Leading figures are ... Dr. Torsten N. Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, ...
(Date:5/3/2016)... ... ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) Center — ... procedures in an environment that looks and feels real. , Located in the heart ... “hackers” to develop and test new devices or software platforms and see how they ...
(Date:5/3/2016)... ... ... Park Cities Pet Sitter has openings for both full-time and part-time ... 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These zip codes ... and Park Cities areas of the Metroplex. Candidates must love animals, have attention ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... industry, announced today that Legacy Health is expanding its use of Intrigma’s cloud-based ... a highly successful initial proof of concept. The Portland, Oregon based health system ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology: